SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma

NCT06794775 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

128

Enrollment

OTHER

Sponsor class

Conditions

Malignant Melanoma Stage III

Interventions

DRUG: Nivolumab
DRUG: Nivolumab + Ipilimumab

Sponsor

Hildur Helgadottir